Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Олмесартан: доказанная высокая эффективность при артериальной гипертензии. Клинический обзор
Олмесартан: доказанная высокая эффективность при артериальной гипертензии. Клинический обзор
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Scholze JR, Schaefer A, Kreutz R. Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients. Expert Opin Drug Saf 2011.
2. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006; 26 (4): 185–93.
3. Dahlot B, Devereux RD, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
4. Edwards RM, Aiyar N, Ohlstein EH et al . Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992; 260: 175–81.
5. Von Bergmann K, Laeis P, Püchler K et al . Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001; 19 (Suppl. 1): 33–40.
6. Giles TD, Bakris GL, Smith DHG et al. Defining the antihypertensiveproperties of the angiotensinreceptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens 2003; 16: 460–6.
7. Ritz E, Viberti GC, Ruilope LM et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53 (1): 49–57. Epub 2009.
8. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5 (1): 41–50. Erratum in: Am J Cardiovasc Drugs 2005; 5 (3): 209.
9. Nakashima H, Kumagai K. Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 2007; 71 (12): 1977–82.
10. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 (9): 1345–53; discussion 1354–6.
11. Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade on nitric oxide synthesis in rats. Circulation 2000; 101: 305–10.
12. Takemoto M, Egashira K, Tomita H et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621–7.
13. Tomita H, Egashira K, Ohara Y et al. Early induction of transforming growth factor-ß via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998; 32: 273–9.
14. Mizuno M, Sada T, Ikeda M et al. Effects of CS-866 on hypertensive nephropathy in SHR and DOCA rats. Jpn J Pharmacol 1997; 73 (Suppl. 1): 135.
2. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006; 26 (4): 185–93.
3. Dahlot B, Devereux RD, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
4. Edwards RM, Aiyar N, Ohlstein EH et al . Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992; 260: 175–81.
5. Von Bergmann K, Laeis P, Püchler K et al . Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001; 19 (Suppl. 1): 33–40.
6. Giles TD, Bakris GL, Smith DHG et al. Defining the antihypertensiveproperties of the angiotensinreceptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens 2003; 16: 460–6.
7. Ritz E, Viberti GC, Ruilope LM et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53 (1): 49–57. Epub 2009.
8. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5 (1): 41–50. Erratum in: Am J Cardiovasc Drugs 2005; 5 (3): 209.
9. Nakashima H, Kumagai K. Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 2007; 71 (12): 1977–82.
10. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 (9): 1345–53; discussion 1354–6.
11. Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade on nitric oxide synthesis in rats. Circulation 2000; 101: 305–10.
12. Takemoto M, Egashira K, Tomita H et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621–7.
13. Tomita H, Egashira K, Ohara Y et al. Early induction of transforming growth factor-ß via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998; 32: 273–9.
14. Mizuno M, Sada T, Ikeda M et al. Effects of CS-866 on hypertensive nephropathy in SHR and DOCA rats. Jpn J Pharmacol 1997; 73 (Suppl. 1): 135.
Авторы
Л.А.Алексанян, Е.Г.Силина
Кафедра клинической фармакологии МГМСУ
Кафедра клинической фармакологии МГМСУ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.